GP和GEM+NDP方案治疗复发转移性乳腺癌的临床疗效分析

目的探讨吉西他滨联合顺铂(GP方案)和吉西他滨联合奈达铂(GEM+NDP方案)治疗复发转移性乳腺癌的临床疗效及不良反应。方法按照随机原则,将52例复发转移性乳腺癌患者分为GP组(29例)和GEM+NDP组(23例),两种方案均以21天为1个治疗周期,治疗2周期和4周期后比较其临床疗效及不良反应。结果治疗2周期后,GP组和GEM+NDP组的治疗总有效率分别为48.28%和60.87%,差异无统计学意义(P>0.05)。除PD以外的患者继续化疗,化疗4周期后,GP组及GEM+NDP组的总有效率分别为31.58%和50.00%,差异无统计学意义(P>0.05)。GP组及GEM+NDP组Ⅲ级白细胞下降、III级血小板减少、贫血的发生率比较,差异均无统计学意义(P>0.05);GEM+NDP组胃肠道反应的发生率(13.0%)明显低于GP组(69.0%)(P<0.05)。GP组1例发生I度肾功损害(3.4%),5例发生II度肾功损害(17.2%);而GEM+NDP组仅1例I度肾功损害(4.3%),差异有统计学意义(P<0.05)。结论 GP方案和GEM+NDP方案治疗蒽环类和(或)紫杉类耐药的复发转移性晚期乳腺癌的疗效相当,不良反应可以耐受。

Analysis of the Clinical Efficacy of GP and GEM+NDP Regimen in the Treatment of Recurrent and Metastatic Breast Cancer

Objective To analyze the clinical efficacy and toxicities of gemcitabine combined with cisplatin and gemcitabine combined with Nedaplatin （NDP） on recurrent and metastatic breast cancer （MBC）. Methods Fifty-two MBC patients were di-vided into gemcitabline combined with cisplatin （GP） Group （n=29） and gemcitabline combined with nedaplatin （GEM＋NDP） Group （n=23） by using the principle of random assigning. The two treatments took 21 days as a cycle. The clinical efficacy and the toxicities were evaluated after two cycles and four cycles. Results After two cycles, the overall response rate （ORR） was 48.28%and 60.87%respectively in GP Group and GEM＋NDP Group, and there was no significant difference between them （P〉0.05）. Except the PD patients, the others continued to get chemotherapy. After four cycles, the ORR was 31.58%and 50.00%respectively in GP Group and GEM＋NDP Group, and there was still no significant difference between them （P〉0.05）. There were no significant differences between the two groups in the incidence of third degree leucopenia, Third degree throm-bocytopenia and anemia. The incidence of gastrointestinal reaction in GEM＋NDP Group （13.0%） was obviously lower than that of GP Group （69.0%）, with significant difference （P〈0.05）. There was one case （3.4%）of First degree impaired renal function and five cases （17.2%） of Second degree impaired renal function in GP Group, while in GEM＋NDP Group there was only one case （4.3%） of First degree impaired renal function. There were significant differences between them （P〈0.05）. Conclusion GP regimen and GEM＋NDP regimen had similar efficacy in the treatment of anthracycline or taxane-resistant recurrent and meta-static breast cancer, and the toxicities can be tolerated.